Seems like we drop, mms muggs people then rise, they are collecting cheap shares before next news
Petro is here, usually share rises when he turns up
Little more buying and we could be around 7:50, next RNS that could be big one
I feel part of it could be sold and give shareholders divi ,
7 seems to be hard nut to crack, as those bought under 6 may be taking profits, once broken and held , 8 plus my guess
I feel there will be few RNS in coming weeks, finance will be sorted and update on rest and hopefully partnership and sales in USA
RUA is dropping slightly , those profits takers could come back here
This has happened on few shares, today rua was red, now blue, he1 other day dropped to 1p then back to 1.25, shakes happen so does profit taking, those who sold at 9 plus could have deramped to get back in, then ramp and out at 9 again
There is lot going on with this share, raise will be easy , I feel could be in partnership
Jam I am talking about today, look at the price now, some will lose some will win, make your own choices as your own money, no friends on these boards
Gone NT to buy now, I feel close could be over 8 or May be blue, buyers are back now
Genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces that the UK's National Institute for Health and Care Excellence ("NICE") has recommended in draft guidance that the Genedrive® CYP2C19-ID test should be used as the point-of-care ("POC") test of choice before clopidogrel administration in the management of Ischemic Stroke ("IS") and Transient Ischaemic Attack ("TIA") patients.
Clopidogrel is an antiplatelet drug used after IS or TIA to reduce the risk of blood clots that can cause further strokes. Clopidogrel is metabolised into its active form by an enzyme encoded by the CYP2C19 gene which in some people has variations that reduce the enzyme's function which means that clopidogrel does not work as well in these people.
The Genedrive® CYP2C19-ID point of care genetic test uses a single, non-invasive cheek swab sample, and rapidly identifies six important genetic variants of the CYP2C19 gene, which are instrumental in the loss of metabolism function. The Genedrive® System automatically interprets the information for the clinician, allowing prompt administration of an optimised treatment plan.
According to the World Stroke Organization, there are over 77 million people globally who currently have experienced ischaemic stroke and it is estimated by the Stroke Association that there are 100,000 strokes in the UK each year. Suboptimal response to antiplatelet treatment following stroke is common, affecting about 20%-30% of patients in the general UK population, which increases to about 50%-60% in certain ethnic groups.
NICE recommended in the May 2023 draft guidance that people who have just had an IS or TIA should have a CYP2C19 genetic test prior to antiplatelet treatment. Following a public consultation of this draft guidance, which ends on 26 April 2024, final recommendations are expected to be published by NICE on 10 July 2024. Think of how many lives could be saved
Even 7 will look cheap soon, keep trying,
About to turn, feel sorry for those who sold low 5’s or even around 6 ,
Food and Drug Administration ("FDA") progress for the Genedrive® MT-RNR1 pharmacogenetic test (Antibiotic Induced Hearing Loss). The Company is in advanced stages of negotiating a collaboration with a USA-based Medical Group to support a highly cost-effective pathway for the necessary clinical trials
· Distributor agreement in place to support the FDA study and support future sales in the United States, they still have Money in bank,
Https://www.sharecast.com/news/aim-bulletin/genedrive-shares-jump-on-nice-test-recommendation--16542715.html
Also they are talks with USA, so if agreed funding may be needed, but deal done with USA will take this to new highs
People are playing between here and Rua, soon they will dump that and pump here, only bought small amount today
50 percent cheaper now then of days highs, should close around 7.50/8
I bought Rua at 10.75 and sold at 13 , now punt here
This will be back over 8, time to get in